Advising CHEPLAPHARM on successful capital market presence – new credit facilities for EUR 780 million

With a Frankfurt-based team led by partner Thomas K. Schrell, business law firm HKLW advised Cheplapharm Arzneimittel GmbH on refinancing existing loans and promissory note loans.
The new credit facilities with a total volume of EUR 780 million were concluded with Deutsche Bank, HSBC, and Unicredit on the London capital market. Commerzbank, DZ Bank, and Santander additionally support the placement with international investors.
The new credit facilities provide the group with flexible and sustainable long-term financing. In addition to the repayment of existing loans and promissory notes, significant additional liquidity will be available to finance future product acquisitions. The new financing structure offers Cheplapharm significant increases in flexibility at attractive terms. The international market for long-term loans (TLB market) also offers the option of flexible increases to support future growth.
CHEPLAPHARM Arzneimittel GmbH is an internationally operating, family-run pharmaceutical company headquartered in the Hanseatic city of Greifswald with some 200 employees and annual sales of EUR 316 million. It has subsidiaries in Hamburg, Englewood, New Jersey, and France. Founded in 1998, the company produces and sells branded and niche pharmaceutical products worldwide, both in the prescription and OTC segments.  

Counsel to Cheplapharm Arzneimittel GmbH
Heuking Kühn Lüer Wojtek:

Thomas K. W. Schrell, LL.M. (Lead, Banking & Finance)
Anja Harms (Banking & Finance), both Frankfurt

Download as PDF
Download as PDF

You are currently using an outdated and no longer supported browser (Internet Explorer). To ensure the best user experience and save you from possible problems, we recommend that you use a more modern browser.